Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Maryland Stem Cell Research Fund: TEDCO brief highlights clinical progress, economic returns and new manufacturing grants
Summary
At the Jan. 15 Ways and Means briefing, TEDCO representatives described the Maryland Stem Cell Research Fund’s clinical advances, claimed economic returns on state investments and a 2023 Manufacturing Assistance initiative to help stem-cell companies scale in Maryland.
Rashika (last name not specified in the transcript), speaking for TEDCO’s stem-cell portfolio, told the Ways and Means Committee on Jan. 15 that Maryland’s stem-cell program has produced clinical advances and measurable economic returns over its 18-year history.
Rashika said the program has played a role in therapies that she described as curative for some patients — she cited bone marrow and half-match transplantation cases and described clinical examples of children who regained normal lives after treatment. "There are patients who are currently being treated with diabetes and, you know, these treatments are curative treatments," she said. She also described gene-editing advances: "With this gene editing technique called CRISPR, FDA approved last year a treatment where... you fix that gene, and put that treatment these cells back into the patient." (Transcript attribution:…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
